Amwins Group Benefits is now expanding its Gene Therapy Solutions (GTS) program to 15 gene and cell therapies, up from the previous five.
This expanded therapy coverage is made possible through the partnership between Stealth Partner Group and Amwins Accident and Health Underwriters, which aims for sustainable strategies that help employers face unexpected, high-dollar gene therapy claims.
"Expanding from GTS-5 to GTS-15 helps ensure that our clients have the comprehensive support they need to face the high costs of gene therapy treatments while making the process simpler and more efficient. We remain dedicated to offering the best solutions for cost containment, helping employers maximize their budgets while providing cutting-edge protection for their workforce," said Harley Barnes, chief executive officer at Stealth Partner Group.
GTS-15 covers 11 of the 13 approved gene therapies, three cell therapy treatments, and one maintenance medication. Diseases covered under the GTS-15 program include Leber congenital amaurosis, spinal muscular atrophy types 1 and 2 for children ages 2 and under, beta thalassemia, cerebral adrenoleukodystrophy, hemophilia A, hemophilia B, Duchenne muscular dystrophy, sickle cell disease, transfusion-dependent beta thalassemia, metachromatic leukodystrophy, multiple myeloma, and congenital athymia.
"Gene therapy is transforming the lives of patients, but with treatment costs reaching up to $4.25 million, this is a challenge that employers shouldn't face alone," said Meredith Hunter, senior vice president at Stealth Partner Group. "Our GTS-15 program provides the critical support needed to keep employers ahead of these rising costs while ensuring the best care for their employees."
The program provides meaningful protection through first-dollar reimbursement to the plan sponsor, covering costs up to the specified deductible while managing any expenses beyond that through the stop-loss carrier, helping to mitigate future rate increases. It also allows for portability, enabling sponsors to change carriers without disrupting coverage.
With Amwins' industry expertise, experts monitor FDA approvals and make strategic program enhancements to add value. Additionally, billing and administration are simplified by including the program fee in the stop-loss bill, reducing the administrative burden.
For a full list of covered treatments and more information, visit the Amwins Gene Therapy Solutions website.
